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Abstract
Nanomaterials, including nanoparticles and nanoobjects, are being incorporated into everyday 
products at an increasing rate. These products include consumer products of interest to 
toxicologists such as pharmaceuticals, cosmetics, food, food packaging, household products, and 
so on. The manufacturing of products containing or utilizing nanomaterials in their composition 
may also present potential toxicologic concerns in the workplace. The molecular complexity and 
composition of these nanomaterials are ever increasing, and the means and methods being applied 
to characterize and perform useful toxicologic assessments are rapidly advancing. This article 
includes presentations by experienced toxicologists in the nanotoxicology community who are 
focused on the applied aspect of the discipline toward supporting state of the art toxicologic 
assessments for food products and packaging, pharmaceuticals and medical devices, inhaled 
nanoparticle and gastrointestinal exposures, and addressing occupational safety and health issues 
and concerns. This symposium overview article summarizes 5 talks that were presented at the 35th 
Annual meeting of the American College of Toxicology on the subject of “Applied 
Nanotechnology.”
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Introduction to Applied Nanomaterial Toxicology and Applied 
Nanotoxicology for Pharmaceuticals and Medical Devices
Dave Hobson, LoneStar PharmTox LLC, Bergheim, TX, USA
In the universe, particles come in a wide range of sizes, shapes, and compositions. Life on 
earth involves and, in fact, requires particles of many types including nanoparticles. The 
atmosphere of our planet is so laden with particles, including nanoparticles, that even on the 
clearest of days at the right vantage point, we can easily observe the light scattering effects 
of these particles. (see Figure 1 showing a view over and across the atmosphere from 10,000 
m).
Without light being scattered by nanoparticles, our sunrises and sunsets would not be as 
beautiful. So living with nanoparticles is not exactly new. The nanoparticles that are ever 
present in our atmosphere such as ocean spray, volcanic ash, airborne soil sediment, and 
even man-made emissions such as industrial smoke, dust and vapor have been around us for 
a very long time and, in some cases, even since life began on our planet. In fact, when we 
examine biologic systems closely enough, we find that structures and particles with 
nanometer dimensions are essential for life.
Our ability to manufacture and engineer nanomaterials or in other words “control” matter at 
the nanoscale at dimensions between approximately 1 and 100 nanometers is termed 
“nanotechnology” and is relatively new. In this range, unique phenomena that enable the 
novel applications occur and have become an exciting and promising new dimension in our 
ability to design and develop new products in essentially every area of human endeavor. 
Nanotechnology encompasses nanoscale science and nanoengineering that involves imaging, 
measuring, modeling, and manipulating matter at the nanoscale.1 Figure 2 provides and 
example classification and descriptors for nanomaterials based on nanoscale dimensions.
With the development of current and emerging technology to manipulate matter in the 
nanoscale and even atomic range, we have arrived at a point where essentially any feasible 
molecular structure to include a vast number of nuclides can be engineered and constructed 
at will.
The rapidly growing number of engineered nanoproducts in development and commerce 
includes products that are of more concern for potential toxicologic effects than others. 
Those of greatest concern typically require contact with biologic systems and include uses in 
pharmaceuticals, medical devices, cosmetics, etc. and so on. While items such as electronics, 
use in polymers and coatings, glass, and plastics where the nanomaterials are permanently 
bound in a larger molecular structure or are otherwise not generally available for biologic 
contact would be of less concern.
A size oriented, toxicologic perspective of nanomaterial exposure to biologic systems is 
shown in Figure 3 are within the size range where cellular structures and biomolecules 
occur. So, in addition to their chemical features, some nanomaterials also have structural 
features that could lead to a potential for adverse biologic effects.
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• inhalation and gastrointestinal absorption;
• uptake into cells and transcytosis across cells;
• distribution into the blood and lymph circulation to reach potentially sensitive 
target sites such as bone marrow, lymph nodes, spleen, liver, kidneys, and heart;
• brain entry via nasal nerves (eg, polio virus);
• recognition and processing by the immune system;
• entry into the cell nucleus;
• … and other toxicologically significant processes.
Because the study of biology does in fact require that we develop an understanding of the 
practical aspects of exposure to various naturally occurring particles including smoke, ash, 
aerosols, and even viruses (which can be viewed as quite elegant nanoparticles in many 
cases), we do already possess a fundamental concept of the hazard range that nanoparticles 
could affect. Natural aerosols such as ocean spray, dust, and smoke at natural and 
atmospheric levels would be generally be considered to be low hazard, whereas exposure to 
the most pathogenic viruses at naturally occurring levels might be considered to be high 
hazard. So, what we don’t know is where the nanomaterials that we engineer occur on the 
scale of hazard within this range.
The developing area of toxicology termed “nanotoxicology” is addressing the issues and 
developing the tools necessary to evaluate the toxicologic characteristics and safety of 
engineered nanomaterials (ENMs).2,3 One of the fundamental questions that this area of 
toxicology, that this subdiscipline seeks to answer is “why might nanoparticles be inherently 
more toxic than the substances of which they are composed?”
Already some significant issues that require careful consideration of nanotoxicology 
findings can be observed. Doak et al4 notes that “nanomaterials cannot be treated in the 
same manner as chemical compounds with regards to their safety assessment, as their unique 
physico-chemical properties are also responsible for unexpected interactions with 
experimental components that generate misleading data-sets.” Most nanotoxicity studies 
(>70%) have been and are currently being done in vitro, using a wide variety of models, 
many of which have not been validated to in vivo observed toxicologic effects. There are 
very few “control” or “standard” reference nanomaterials available for use in the conduct of 
nanotoxicologic studies, and the degree and methods used in test article characterization for 
many published nanotoxicology studies are substantially variable to the extent that in many 
cases, the studies could not be duplicated as state-of-the-art toxicologic science would 
demand.
This is a fast emerging and developing area of technology, and at the rate at which some new 
nanomaterials are being developed, collecting essential toxicological information presents a 
road block, and high throughput screening techniques are being proposed and developed for 
toxicologic assessment with significant focus on the following aspects:
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• absorption, distribution, toxicokinetics, and metabolism in vivo still must be 
understood,
• targets and mechanism(s) of action must be identified in vivo and evaluated, and
• routes and rates of elimination must be identified and characterized.
The observation that, in biologic systems, nanoparticles often are not best characterized by 
their fundamental material characteristics of size, shape, surface features, and composition 
but rather by the protein “corona” that coats them following exposure to the biologic 
systems appears to be of fundamental significance in understanding how nanoparticles and 
nanomaterials interact with these systems.5–7 The “corona” that coats nanoparticles is a 
natural process that covers the particle with a combination of “hard,” nanoparticle-bound 
protein that is itself then covered with “soft” proteins that are weakly bound to the hard 
protein surfaces. The formation of the corona on a nanoparticle appears to be 
pharmacologically and toxicologically very significant to its biologic activity. The corona 
proteins may be nanoparticle unique, and thousands of different types of proteins may be 
involved. Immune system recognition, cellular processing, biodistribution, kinetics, 
elimination, and so on may be affected individually or in combination.
The use of nanotechnology in medical pharmaceuticals and medical devices may involve 
one or more of the following characteristics:
• improvement/modification of solubility and/or absorption/distribution/
metabolism,
• improvement of formulation stability,
• increase excipient solubility and reduce excipient use,
• patent extension/new patents (new active pharmaceutical ingredient [API] forms/
formulations),
• nanotechnology targeted new molecular/biologic entity forms that reduce 
exposure and toxicity,
• modification of device surface properties of medical devices, and
• enhancement of device function (ie, molecular targeting, nanobrachytherapy, and 
so on).
Regulatory agencies such as the US Food and Drug Administration (FDA) and the European 
Medicines Agency already have some familiarity with the incorporation of nanotechnology 
in pharmaceutical and medical device products. They are continuously learning and 
improving their ability to understand the unique and potentially beneficial characteristics 
that the use of nanotechnology may provide to their regulated products. The evaluation of 
product safety for each nanomaterial containing product is taken on a case-by-case basis, 
and it is generally thought that current regulations for medicines and medical devices are 
sufficiently stringent and comprehensive in scope to cover the theoretical risks associated 
with nanomaterials. Guidance is in place that requires nanomaterials used in pharmaceutical 
products be reported and that pharmaceuticals containing nanotechnology be closely 
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evaluated for safety using state of the science risk/benefit principles. The US FDA has 
currently approved over 20 products that use nanotechnology.
Some examples of nanotechnology-enabled, medical products in development include 
cancer therapeutics utilizing nanoparticles to improve tumor targeting and localization; 
radioisotopic nanoparticles (Au, Fe, In, etc); and active pharmaceutical carrying liposomal, 
polymeric, solid-lipid nanoparticles (SLNs), and so on.
Pharmacokinetics of a nanoparticle-incorporated drug substance can be modified by 
changing the surface characteristics of polymeric (eg, polyethylene–polyethylene glycol 
[PEG]) SLNs by using amphiphilic solvation enhancers.8 This type of strategy opens up a 
wide variety of nanoparticle—API— strategies that can now be developed and tried. 
Antiretroviral HIV/AIDS drug delivery with macrophage targeted peptide-PEG nanocarriers, 
for example, increases cellular uptake and increases accumulation in macrophages of liver, 
kidney, and spleen compared with those which are nontargeted.9 This type of nanocarrier 
targeting increases antiretroviral concentrations where needed, with longer persistence and 
can result in decreased systemic toxicity.
Nanoliposomal therapeutics are being developed that exhibit low toxicity, are predominately 
metabolized and/or are excreted via the lymphatics, and can be prepared with a variety of 
APIs. Diagnostic radiolabels can be incorporated and used to image and monitor API 
delivery to target tissues as well as observed therapeutic efficacy.10
Targeted nanotherapeutics typically have 4 components in their design consisting of:
1. a particle matrix composed of a polymer, lipid, solid, carbon, or other type of 
nanostructure (eg, dendrimers),
2. a pharmaceutical active that is a small molecule or biopharmaceutical,
3. a surface functionalization component, and
4. a targeting ligand.
Doxil, for example, is a nanoliposomal drug that is “passively targeted” to tumors and 
releases doxorubicin to the tumor tissue after targeting. Other nanoenabled drug products in 
development include products that use target-specific targeting such as oral parathyroid 
hormone for bone loss and oral clotting factors for hemophilia (both currently in preclinical 
development), a glycolipodepsipeptide antibiotic for grampositive bacteria (currently in 
phase 2), and a number of cancer therapeutics and theragnostic combinations of API and 
imaging agent in early stage discovery and development. Recent reviews of targeted 
nanotherapeutics provide more information with respect to this area of development.12,13
Examples of FDA-cleared pharmaceuticals listed by general nanocarrier type and 
therapeutic indications include the following:
• Liposomals
– Liposomal amphotericin B—mycotic infection
– Liposomal daunorubicin (DaunoXome)—Kaposi sarcoma
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– Cytarabine liposome injection (Depocyt)—lymphomatous meningitis
– Collagran MMP inhibiting—wound dressings
– “Stealth” liposome doxorubicin—Kaposi sarcoma
– Doxil/Caelyx—ovarian/breast cancer
– Verteporfin liposomal (Visudyne)—Wet macular degeneration
• Solid polymeric
– Carmustine (Gliadel)—Glioblastoma multiforme
– Abraxane (nanoparticles of paclitaxel-taxol)— Mammary cancer 
(metastitic)
– TrivCor (nanoparticulate form)—high cholesterol treatment
• PEGylated
– PEG-succinimidyl-L-asparaginase—lymphoblastic leukemia
– PEG-adenosine deaminase—serius immunodeficiency
– PEG-interferon −2α (Pegasyls)—Hepatitis C
• Nanocrystal
– Emend nanocrystals—nausea prevention in chemotherapy
– Rapamune nanocrystal—rejection prevention
Over the past few years, a number of lessons have been learned regarding the conduct drug 
safety studies and the interpretation of data from these studies. Some of these include the 
following:
• Dose expression needs to include particulate properties (dimension, shape, 
surface characteristics, charge, aggregation/agglomeration state, and so on) as 
well as chemical composition.
• Determination of biodistribution and kinetics while difficult is very important. 
TEM (Transmission electron microscopy) is still the “gold standard” but new 
techniques (eg, hyperspectral imaging) are emerging.
• The immunological recognition and protein coronal affinity properties of 
nanoparticles can be significant and must not be overlooked.
• Whole animal perspective must be maintained even when using in vitro methods 
to isolate and evaluate specific processes as necessary.
• When a nondigestable nanoparticle becomes bound and sequestered in the liver 
reticuloendothelial system (or some other tissue sites), there may be reason for 
concern that it might not have a route of elimination other than cremation.
Therefore, for these and other reasons, studies with nanomaterials intended for therapeutic 
use need to carefully characterize and evaluate nanoparticles used in the delivery system or 
pharmaceutical ingredient itself as they enter, distribute, and are eliminated by the body.
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When used in medical devices, the primary toxicologic concern is for exposure to 
“unbound” nanomaterials. Many devices that employ nanotechnology may not require 
extensive safety evaluation if it can be established that by design and relevant data the 
nanomaterial is not bioavailable. In vitro diagnostic tests that employ nanotechnology 
generally would not require in vivo safety or biocompatibility evaluation. In all cases, the 
manufacturer is responsible for demonstrating that there is a lack of potential exposure to 
nanomaterials used in the device. The FDA Draft Guidance for Industry (April 2013) 
entitled “Use of International Standard ISO-10993, Biological Evaluation of Medical 
Devices Part 1: Evaluation and Testing” specifically addresses submicron or nanotechnology 
medical device components.14 This guidance clearly indicates that considerations for dose 
characterization and the design and conduct of safety studies will have to take into 
consideration the unique properties of these materials.
In conclusion, life depends as well as has adapted to the presence of naturally occurring 
nanostructures and nanomaterials. Modern science and engineering have now developed the 
ability to make and manufacture nanomaterials for an expanding variety of purposes, 
including many that involve direct exposure to biologic systems. Nanotoxicology has 
emerged as a subdiscipline of toxicology needed to support the discovery and development 
of safe nanotechnology products. Therefore, “applied nanotoxicology” incorporates an 
ongoing and comprehensive understanding of the state of the science of both 
nanotechnology and nanotoxicology toward development of practices and products that 
safely employ and utilize nanotechnology where exposure to biologic systems is possible.
Uptake and Distribution of Ingested Nanomaterials
Stephen M. Roberts and Georgia K. Hinkley, Univ. of Florida, Gainesville, FL, USA
There are several challenges in conducting studies on the biological fate and effects of 
nanomaterials. These challenges include (1) inconsistency in nanomaterials available for 
study, for example, lot-to-lot variations in important characteristics such as size, shape, and 
surface properties, and deviations from the labeled description; (2) limitations in quantities 
available for study; (3) uncertainty as to the proper dose metric (eg, mass vs surface area vs 
particle concentration); (4) difficulty detecting and quantifying nanomaterials in tissues; and 
(5) changing chemical and physical properties of nanomaterials with time, handling, and in 
biological environments.
To these challenges, several others are added when studying ingested nanomaterials due to 
the inherent complexity of the gastrointestinal tract (GIT). As ingested nanomaterials transit 
the GIT, their immediate environment changes in several ways that can affect nanomaterial 
properties thought to influence biological activity, including size, shape, and surface 
properties such as charge, catalytic properties, and adsorbed materials (ie, their “corona”). 
Examples of changes in the dynamic environment of the GIT include pH, ionic strength and 
composition of GIT fluids, and microflora and digested food matrices with which 
nanoparticles can interact. Absorptive surfaces also change, as nanomaterials pass through 
the GIT in terms of surface area, absorption mechanisms in play, and thickness of the 
protective mucin layer.
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In order for ingested nanomaterials to be absorbed from the GIT, they must overcome 
several barriers (Figure 4). They must survive the low pH, high ionic environment of the 
stomach, where they may be dissolved, extensively agglomerated, or coated with 
macromolecules, altering their surface properties. In the intestine, they must be able to 
penetrate the mucin layer (Figure 5).15 Previous studies have shown that, in general, smaller 
size favors movement through the mucin layer,16 and neutral particles move the fastest, 
followed by positively charged particles, with negatively charged particles moving the 
slowest.17 Coatings such as chitosan, latex, and PEG can increase the rate of movement of 
nanoparticles through mucin.16,18
Finally, nanoparticles must be able to pass through the epithelial lining of the GIT. Uptake 
can be passive, through transcellular, paracellular, or cell turnover processes, or active (eg, 
clathrin mediated and caveolar mediated). Uptake through the lymphatics can occur in 
specialized cells in Peyer’s patches.
Unfortunately, most studies of nanoparticle uptake treat the GIT as a “black box.” 
Nanomaterials are characterized before dosing, and tissues are analyzed over time for the 
presence of nanomaterials. Because these studies do not follow events within the GIT, no 
insight is provided as to how the nanoparticles change in the dynamic GIT environment, and 
most importantly, the characteristics of the particles when they reach the absorptive surfaces 
of the gut. This greatly limits our ability to gain understanding of how and why nanoparticle 
characteristics affect their uptake into the body.
Among the few studies that have attempted to measure the bioavailability of orally 
administered nanomaterials, the results have been uniformly low. For example, Schleh et 
al19 measured the bioavailability of native gold particles in sizes ranging from 1.4 to 200 
nm, some with surface modifications to produce positive or negative charges. The 
bioavailabilities of all of the nanoparticles were less than 1%. Explaining findings such as 
these is difficult because the extent of agglomeration that took place within the GIT, and 
therefore the actual size of the gold particles when they reached the intestinal epithelium, is 
unknown. If nearly all of the primary particles were extensively agglomerated into particles 
too large to penetrate the mucin lining of the GIT or be taken up by any of the particle 
uptake mechanisms, then the uniformly low bioavailabilities are not surprising.
We conducted a study in which the oral bioavailability of uncoated and PEG-coated 20 nm 
gold nanoparticles was compared in mice.20 The agglomeration state of the gold 
nanoparticles in each treatment group was followed within the GIT using transmission 
electron microscopy. Uncoated gold particles agglomerated extensively in the stomach and 
remained as large agglomerates throughout the GIT. Polyethylene glycolcoated gold 
nanoparticles remained as primary particles, and in contrast to the large agglomerates in the 
uncoated gold-treated animals, were able to penetrate the mucin barrier. Mice treated with 
PEG-coated gold nanoparticles had significantly higher nanoparticle concentrations in some 
tissues, but the differences were not striking and the oral bioavailabilities of both the 
uncoated and PEG-gold were low (<1%). These findings suggest that agglomeration state 
can influence uptake but that even with well-dispersed particles, bioavailability of 
nanoparticles is low.
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Are there circumstances in which the oral uptake of solid nanoparticles is sufficient that they 
might serve as effective drug delivery vehicles, or for nontherapeutic particles, as a 
significant health risk? To answer this question, a new generation of studies will be needed 
in which the characteristics (eg, size, surface charge, and adsorbed materials) of orally 
administered nanoparticles are examined in situ, within the GIT, and critical determinants of 
uptake are identified.
Nanoparticles as an Emerging Environmental and Occupational Hazard—
Toxicology Prospective
Anna A. Shvedova, CDC-National Institute for Occupational Safety and Health (NIOSH) and 
WVU, Morgantown, WV, USA
Innovations in the nanotechnology field, with a wide-range of different products, raise the 
issue of potential adverse health effects particularly in occupational and environmental 
settings. Carbonaceous nanomaterials, specifically nanotubes, are among the most widely 
studied and utilized.21 Carbon nanotubes (CNTs) may be single walled (SW) or multiwalled 
(MW); in this presentation, CNT refers to both types while SWCNT refers to SW nanotubes 
only. The production of CNT and their composites are increasing globally.22 The CNT 
products have a wide scope of applications and are used in textiles, cosmetics, biomedicine, 
and polymer chemistry in manufacturing of motor vehicles and sports equipment and 
integrated circuits for electronic modules. Human exposure to CNTs is primarily through 
inhalation and dermal contact, especially during the manufacturing and handling 
processes.23 However, the lung is the major portal of unintended CNT entry into the human 
body, potentially leading to pulmonary damage, inflammation, oxidative stress, fibrosis, and 
cancer.24,25
Studies of respiratory toxicity of CNTs following aspiration in C57BL/6 mice revealed that 
these nanomaterials caused a dose-dependent augmentation of biomarkers of cellular injury, 
pulmonary inflammation, lung damage, and increased oxidative stress. This is evidenced by 
increase in oxidation of protein sulfhydryls, reduced level of glutathione, and total 
antioxidant reserve along with the accumulation of lipid peroxidation products found in 
bronchoalveolar lavage fluid and in the lung following pharyngeal aspiration and inhalation 
exposures.26 Moreover, markers of pulmonary cytotoxicity were associated with early 
development of acute inflammation, collagen accumulation, and progressive fibrosis and 
formation of granulomas. A subsequent study using C57BL/6 mice that were maintained on 
vitamin E-sufficient or vitamin E-deficient diets further emphasized the importance of 
oxidative stress and anti-oxidant depletion in the overall inflammatory response insofar as 
the toxicity of SWCNTs and the fibrotic responses (enhanced collagen deposition) were 
significantly higher in the latter group of mice, lacking the major lipid-soluble antioxidant, 
vitamin E.27 Overall, pharyngeal aspiration of SWCNTs elicits a robust acute inflammatory 
response, with early onset of progressive pulmonary fibrosis whose expression and severity 
are associated with the intensity of oxidative stress in the lung of the exposed C57BL/6 
mice.
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The most commonly used technologies in the manufacturing of CNTs rely heavily on the 
use of catalytically active metals, either iron or nickel. As a result, the final material could 
potentially contain significant amounts (up to 30–40 wt%) of these metals that may act as 
catalysts of oxidative stress. Indeed, many in vitro studies of CNTs appear to describe 
adverse effects of these contaminants and not of the nanotubes themselves.28–30 A number 
of other reports have indicated elevated oxidative stress in response to CNT employing cell-
free models and in vitro cell exposures; however, in many cases, these studies could have 
false outcomes. By employing in vivo electron spin resonance (ESR) spin-trapping 
technology to directly record free radical formation along with redox assessments of 
antioxidant balance, we were able to reveal that CNT—in doses relevant to potential 
occupational exposures—exerts their toxic effects in the lung and distant organs (heart and 
liver) of exposed animals. We reported that exposure to partially purified CNTs (HiPco, 
CNI, Inc, Texas) resulted in the augmentation of oxidative stress as evidenced by ESR 
detection of a-(4-pyridyl-1-oxide)-N-tert-butylnitrone spin-trapped carbon-centered lipid-
derived radicals recorded shortly after the treatment. This was accompanied by a significant 
depletion of antioxidants and elevated biomarkers of inflammation presented by recruitment 
of inflammatory cells and an increase in proinflammatory cytokines in the lungs as well as 
development of multifocal granulomatous pneumonia, interstitial fibrosis, and suppressed 
pulmonary function. Moreover, pulmonary exposure to SWCNTs also caused the formation 
of carbon-centered, lipid-derived radicals in the heart and liver at later time points (day 7 
postexposures). Additionally, CNTs induced a significant accumulation of oxidatively 
modified proteins, an increase in lipid peroxidation products, depletion of antioxidants, and 
an inflammatory response in both the heart and the liver. Furthermore, the iron chelator 
deferoxamine noticeably reduced lung inflammation and oxidative stress, indicating an 
important role of metal-catalyzed species in lung injury caused by CNTs. Overall, this study 
for the first time provided direct evidence that lipid-derived free radicals are a critical 
contributor to tissue damage induced by CNTs not only in the lungs but in distant organs.31
Realistic exposures to CNT may occur in conjunction with other pathogenic impacts 
(microbial infections) and trigger enhanced responses. Sequential exposure to CNT and 
Listeria monocytogenes (LM) amplified lung inflammation and collagen formation. Notably, 
despite the robust inflammatory response, CNT pre-exposure significantly decreased the 
pulmonary clearance of LM-exposed mice measured 3 to 7 days after microbial infection 
versus vehicle/LM-treated mice. We established that decreased bacterial clearance in CNT-
preexposed mice was associated with suppressed phagocytosis of bacteria by macrophages 
and a decrease in nitric oxide production by the phagocytes. Preincubation of primarily 
murine alveolar macrophages with SWCNT in vitro also resulted in reduced nitric oxide 
generation and suppressed phagocytizing activity toward LM. Failure of SWCNT-exposed 
mice to clear LM led to a continued elevation in nearly all major chemokines and acute-
phase cytokines into the later course of infection. Overall, these data indicate that enhanced 
acute inflammation and pulmonary injury with delayed bacterial clearance after CNT 
exposure may lead to increased susceptibility to lung infection in exposed populations.32
Multidisciplinary studies combining proteomics analysis with assessments of changes in 
pulmonary morphology (including collagen) in the lung samples recovered from mice 
exposed to CNT, carbon black, and asbestos in doses relevant to potential occupational 
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exposures are of particular value. Global proteomic analysis revealed that 69% and 93% of 
proteins affected by asbestos and carbon black were also affected by CNT exposure, 
demonstrating that the asbestos and carbon responses can be considered a subset of the 
proteins and biological pathways affected by CNT. The CNT treatment caused the greatest 
changes in abundance of identified lung tissue proteins. The trend in number of proteins 
affected (CNT [376] > asbestos [231] > UFCB [184]) was similar to inflammatory cytokine 
responses seen in bronchiolar lavage and lung tissue.33 Overall, a significantly smaller 
number of proteins were affected by asbestos and carbon black treatment than for CNT.
Exposure to engineered carbonaceous nanomaterials, including CNT and nanofibers, is 
considered a potential health hazard based on their physical similarities with asbestos. 
Carbon nanotubes may also be as pathogenic as asbestiform fibers because of their shape, 
dimensions, and high aspect ratio, biopersistence, and capacity to generate reactive oxygen 
species, oxidative stress, and genotoxicity.34–38 The resemblance of the fibrous needle-like 
shape to asbestos has raised further concerns regarding the potential carcinogenicity of CNT 
or their effects on tumor–hosts relationships and growth of tumors in the body. Chronic 
exposure to CNT was shown to induce DNA damage and increase mutation frequency in 
mouse embryonic cells and human epithelial cells.39,40 Carbon nanotubes induce mitotic 
abnormality with 1 rather than 2 mitotic spindle poles, a potential mechanism that impaired 
cell division.41 Many studies have reported that CNT can induce apoptosis, DNA damage, 
and activation of major regulatory pathways—MAPKs (Mitogen-Activated Protein Kinase), 
AP-1 (Activator Protein Factor-1), NF-κB (Nuclear Factor kappa B), and Akt (Protein 
Kinase B)— all of which recapitulate key molecular events involved in asbestos-induced 
lung cancer.41,42 Recently, we have demonstrated that a single exposure to inhalable CNT 
accelerated metastatic growth in lung of mice.43 In particular, we observed that acute 
exposure to CNT facilitated accumulation of lung-associated, myeloid-derived suppressor 
cells (MDSC) and promoted lung tumor growth. This was achieved by alterations in the 
tissue microenvironment that enabled early recruitment of MDSC to the lungs, as depletion 
of MDSC abrogates protumor effects of acute exposure to CNT.43
In conclusion, the growing use of nanomaterials for consumer products, food packaging, and 
biomedicine imply their increasing levels of manufacturing. Carbon nanotubes hold great 
potential as a promising material for a number of applications in various electronic, 
chemical, and bioengineering fields; however, major knowledge gaps still exist with respect 
to the effects of CNT on humans.23,25,44 The use of CNTs has increased substantially in the 
last decade and is expected to grow in the near future.45 Considering the potential health 
implications and increasing, widespread use of CNTs, comprehensive toxicology data and 
risk assessment—integrated with a life-cycle perspective—is necessary for the development 
of new safe-by-design nanomaterials and hence nanoapplications.
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Consumer Product Example: Strategies for Setting Occupational Exposure 
Limits for Engineered Titanium Dioxide Nanomaterials
David B. Warheit, Chemours Company, Wilmington, DE, USA
Titanium dioxide (TiO2) particles can be found in nature but generally are synthesized from 
minerals such ilmenite, rutile, or anatase. Titanium dioxide particles have a variety of 
applications, although the most common forms are utilized in pigments and paints. This is 
due, primarily, to the physicochemical properties of these particle types, particularly 
optimized within a certain particle size range (~200–300 nm).46 This results in a high 
refractive index feature, providing the properties of brightness and natural white coloring. 
These characteristics are often referred to as “opacifier” properties which facilitate color 
optimization—essential properties necessary for use in applications such as paints, papers, 
plastics, coatings, and food items.
It is important to note that not all forms of TiO2 are alike— both compositionally and/or 
from a hazard standpoint. In this regard, physicochemical composition of TiO2 particles in 
various products is specified for the particular commercial application/function. For 
example, some common commercial applications (1) exist in the form of opacifiers (white 
pigments used in paints and cosmetics), (2) as ultraviolet ray scavengers (in sunscreens), or 
(3) in catalytic functions. The composition or various forms of TiO2 particles in these 
products can have different crystal structures (rutile or anatase or combinations of the 2 
forms), different particle sizes, and corresponding surface area metrics as well as significant 
differences in particle surface characteristics (i.e., neutralized vs. naked surfaces); and 
different surface coatings versus uncoated surfaces. For instance, “catalytic forms” are very 
different from pigments” from a physicochemical characteristics standpoint, although both 
are identified as polymorphs of TiO2 particles. Catalytic and photocatalyst functions favor 
enhanced “surface reactivity” effects (ie, “naked” particle surfaces to facilitate/catalyze 
reactions).
Although TiO2 particles are generally known as low-toxicity materials, there can be some 
potency differences when assessing hazard effects following inhalation exposures.
The major routes of TiO2 particle and nanoparticle exposure occur via 3 entry portals. These 
are identified as (1) oral exposures—primarily via food consumption; (2) dermal exposures
—often through cosmetic and sunscreen applications; and (3) inhalation exposures—
primarily under occupational and manufacturing (workplace) conditions. The focus of the 
presentation concerned the implementation of occupational exposure levels in the workplace 
using pulmonary bridging or read across methodologies.
The development of occupational exposure limits (OELs) can be implemented by 
considering both the pulmonary toxicity and the epidemiological data available for the 
different forms of TiO2 particulates. For TiO2 particles in particular, physicochemical 
parameters to be evaluated should include crystal structure conformation, surface area, 
particle size distributions in relevant media, as well as composition/surface coatings, surface 
reactivity, method of nanomaterial synthesis method, and impurities. As an illustration of 
potential lung hazards, pulmonary bioassay studies comparing 3 different ultrafine TiO2 
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particle types resulted in development of hazard profiles which could then be bridged (or 
read-across) to the extensive database record of the pigment-grade particulate form of 
TiO2.47,48,49 Assessments of the toxicity data documented in studies, along with 
consideration of epidemiological findings in TiO2 occupational workers, concomitant with 
bridging (read-across) comparisons provided in estimated OEL values of 1 mg/m3, 2 mg/m3, 
and 5 mg/m3, respectively, for the high surface reactivity anatase-rutile uf-TiO2 form, low 
surface reactivity uf-TiO2 forms, as well as pigment-grade TiO2 particle types, respectively. 
The values obtained in this process differ from the NIOSH-recommended exposure levels 
for uf-TiO2. In this regard, NIOSH utilized a different methodology, which lacked a 
comprehensive evaluation of physicochemical characterization and species-related 
biological responses.
Recently, a workshop was conducted with the objective of comparing and evaluating 
different strategies for developing OELs for ENMs.50 A number of approaches were 
presented at this meeting for setting OELs for ENMs, since it will be impossible to generate 
experimental inhalation toxicity or epidemiological data on the various forms of particles or 
nanoparticles in commerce. The publication by Gordon and colleagues50 reviewed the 
workshop findings and identified areas for additional research. During this workshop, 
Warheit49 proposed a bridging approach to estimate OELs for 3 forms of nano-TiO2 
particulates, based upon comparative results of pulmonary bioassay/intratracheal instillation 
toxicity studies and bridging or benchmarking the results to a rather complete subchronic 
and long-term, dose–response database of inhalation studies in rats with pigment-grade TiO2 
particles. In addition, a rather extensive database of >4 epidemiological studies covering >23 
000 TiO2-exposed workers were included in the analysis. This application of the data could 
provide a useful and practical methodology for estimating occupational exposure limits, in 
the absence of a complete toxicological data set on the various forms of nanoscale TiO2 
particles. A schematic example of bridging studies to estimate occupational exposure levels 
using pulmonary bioassay studies to longer term inhalation studies is demonstrated in Figure 
6.
Applied Considerations for Safety Assessment of Food Products and Food 
Packaging Containing Nanomaterials
Robin C. Guy, Robin Guy Consulting LLC, Lake Forest, IL, USA
Food Applications—Nanofood ingredients are present in many foods and food contact 
items. Foods have contained natural nanofood ingredients for hundreds of years. 
Mayonnaise and some dairy products, for example, are foods that may contain natural-
occurring nanomaterials in emulsions. Engineered nanofood ingredients are now used in 
many food applications, mostly as food additives and dietary supplements. These ingredients 
may be used to alter or enhance a food’s appearance, color, flavor, sweet/sour perception, 
odor, or texture. Nanofood ingredients may also be used to decrease or increase absorption 
or act as a preservative.
Food contact items are materials that come in contact with food but are not intended to be 
consumed directly. Food contact products with nano-sized ingredients are being used in a 
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wide variety of applications. These applications may include indicators of freshness and 
those to extend product shelf-life, detection of contamination or spoilage, UV barriers, 
increase of packaging strength, water resistant barriers, radio frequency identification, 
nanosized barcodes, trademark and fraud protection, and packaging for extreme hot, extreme 
cold, and aerospace conditions.
Food-Related Applications—Nano-sized materials may also be found in agriculture and 
food production. Applications may include controlled release of fertilizers and nutrients, 
specific targeted delivery of nutrients and pesticides to crops, treatment of microbial and 
chemical soil contaminants, nano-sized sensors used to monitor livestock and crops, and the 
use of encapsulated vaccines for livestock. Water may even be treated or come in contact 
with nano-sized particles during filtration processes. For example, procedures exist for the 
“nanofiltration” of water, including reverse-osmosis procedures for desalination, and to 
remove hardness, pesticides, metals, viruses, and bacteria.
Regulatory—The US FDA has Guidance Documents to assist with nanomaterial safety 
testing and approval considerations. The guidance51 Considering Whether an FDA-
Regulated Product Involves the Application of Nanotechnology, issued June 24, 2014, 
describes FDA’s current thinking on determining whether FDA-regulated products involve 
the application of nanotechnology. This guidance identifies 2 points to consider that should 
be used to evaluate whether FDA-regulated products involve the application of 
nanotechnology. These points address both particle dimensions and dimension-dependent 
properties or phenomena.
The guidance52 Assessing the Effects of Significant Manufacturing Process Changes, 
Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients 
and Food Contact Substances, Including Food Ingredients that Are Color Additives, issued 
June 24, 2014, discusses the safety assessment of a food substance including the following 
considerations: identity, technical effect, self-limiting levels of use, dietary exposure and 
safety studies, manufacturing process, and how manufacturing changes affect the safety and 
regulatory status.
The European Commission has a regulation that addresses manufacturing changes to an item 
on the community list.53 The regulation states that when a food additive is already included 
in a community list and there is a significant change in its production methods or in the 
starting materials used, or there is a change in particle size, for example, through 
nanotechnology, the food additive prepared by those new methods or materials shall be 
considered as a different additive and a new entry in the community lists or a change in the 
specifications shall be required before it can be placed on the market.
The European Union also regulates food contact ingredients.54 This regulation states that 
new technologies that engineer substances in particle size that exhibit chemical and physical 
properties that significantly differ from those at a larger scale, for example, nanoparticles, 
should be assessed on a case-by-case basis as regard their risk until more information is 
known about such new technology.
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The European Food Safety Authority Scientific Committee developed a scientific opinion 
entitled, Guidance on the risk assessment of the application of nanoscience and 
nanotechnologies in the food and feed chain.55
The US FDA has several options for getting products containing nanoingredients on the US 
market.
1. Generally Recognized as Safe (GRAS): Types of GRAS includes GRAS 
Determination, GRAS Self-Affirmation, and Flavor and Extract Manufacturer’s 
Association GRAS. GRAS, through scientific procedures, requires the same 
quantity and quality of scientific evidence as is required to obtain approval of the 
substance as a food additive and may be based upon published studies, which 
may also be supported by unpublished studies and other data and information. 
The lack of transparency with Self-Affirmations remains a safety concern. The 
Grocery Manufacturer’s Association launched an initiative to improve the GRAS 
process in 2014 to provide clear guidance on how to conduct transparent state of 
the art ingredient safety assessments.56 The FDA publishes GRAS Determination 
information on the FDA Web site.
2. New Dietary Ingredient Notification: FDA’s New Dietary Ingredient Notification 
Draft guidance57: NDI is defined by statute as a dietary ingredient that was not 
marketed in the United States before October 15, 1994. The submission should 
include a description of the identity and composition of the nanomaterial, a basis 
for the conclusion that the substance is an NDI, a description of the conditions of 
use, and an explanation of how the history of use or other evidence of safety 
justifies the conclusion that the dietary supplement containing the NDI will 
reasonably be expected to be safe.
3. Food Additive Petition58: Guidance for Industry and Other Stakeholders: 
Toxicological Principles for the Safety Assessment of Food Ingredients 
(Redbook 2000): The Redbook gives guidance on details on Food Additive 
Petition and discusses how to determine the need for toxicity studies; design, 
conduct, and report results of toxicity studies; conduct statistical analyses of 
data; and review histological data.
4. CVM (Center for Veterinary Medicine) Feed (note: updated with final 
guidance)59: This final guidance identifies potential issues related to safety or 
regulatory status of food for animals containing nanomaterials or otherwise 
involving the application of nanotechnology.
5. EPA (Environmental Protection Agency): In general, producers of pesticide 
products must submit scientific and technical data for EPA review to ensure that 
the use of a pesticide will not generally cause unreasonable adverse effects on 
human health or the environment.
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View across earth’s atmosphere observed over Meteor Crater, AZ, from 10 000 meters. 
Photo by D.W. Hobson
Hobson et al. Page 20














Useful descriptors for nanomaterials.
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A size-oriented toxicologic perspective of nanoparticles.
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Overview of barriers to gastrointestinal absorption of small particles.
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Mucin layer in mouse colon (approximately 10 µm). The thick, unstirred mucin layer is 
constantly being regenerated. In order to gain access to the absorptive surfaces in the 
gastrointestinal tract (GIT), particles must transit the mucin layer in a 4- to 6-hour recycling 
window.
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Schematic demonstrating the strategy for conducting pulmonary bioassay bridging studies. 
Bridging studies can have utility in providing an inexpensive preliminary safety screen when 
evaluating the hazards of new developmental compounds. The basic idea for the bridging 
concept is that the effects of the instilled materials serve as a control (known) material and 
then are “bridged” on the one hand to the inhalation toxicity data for that material and on the 
other hand to the new materials being tested.
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